State Street Corp Raises Stock Holdings in Cibus, Inc. (NASDAQ:CBUS)

State Street Corp grew its stake in shares of Cibus, Inc. (NASDAQ:CBUS) by 43.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 307,262 shares of the company’s stock after buying an additional 93,236 shares during the period. State Street Corp owned 1.16% of Cibus worth $1,002,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in CBUS. SG Americas Securities LLC purchased a new position in Cibus during the third quarter valued at approximately $33,000. HighTower Advisors LLC raised its position in shares of Cibus by 20.6% during the 3rd quarter. HighTower Advisors LLC now owns 16,125 shares of the company’s stock valued at $52,000 after purchasing an additional 2,750 shares during the period. Swan Global Investments LLC purchased a new position in shares of Cibus during the 3rd quarter valued at $115,000. Charles Schwab Investment Management Inc. boosted its holdings in Cibus by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock worth $161,000 after buying an additional 6,276 shares during the period. Finally, FineMark National Bank & Trust increased its stake in Cibus by 24.3% in the 2nd quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock worth $202,000 after buying an additional 4,000 shares in the last quarter. 33.81% of the stock is currently owned by institutional investors.

Cibus Trading Up 6.5 %

Shares of CBUS stock opened at $2.96 on Friday. The stock has a market capitalization of $78.31 million, a price-to-earnings ratio of -0.13 and a beta of 1.86. Cibus, Inc. has a 12-month low of $2.35 and a 12-month high of $23.18. The stock’s 50-day moving average price is $3.99 and its 200-day moving average price is $5.79.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CBUS shares. Alliance Global Partners lowered their price objective on Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a research report on Tuesday, September 24th. Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price target on shares of Cibus in a report on Tuesday, October 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Cibus in a report on Monday, November 11th.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.